Paper Review Records
All Paper Review Records
17 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
244
days
Design, preclinical evaluation, and multicenter phase 1 clinical study of HZ-A-018 for relapsed or refractory central nervous system lymphoma
Authors
Shenglan Li; Jialiang Lu; Zhuang Kang; Haiyan Yang; Wenbin Qian; Xi Chen; Xianggui Yuan; Miao Hu; Qiuqiu Shi; Xinglu Zhou; Feng Chen; Xiaowu Dong; Wenbin LiShow moreShow less
Affiliations
Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou 310022, China; Department of Hematology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China; HealZen Therapeutics Co., Ltd., Hangzhou 310018, China; ZJUCPS-HealZen Joint Laboratory of Drug Innovation and Transformation, Zhejiang University, Hangzhou 310058, ChinaShow moreShow less
140
days
CDK9 inhibition sensitizes intrinsically resistant BRAFV600E mutant colorectal cancer to BRAF inhibitors
Authors
Ning Wei; Natalie Thielen; Mahshid Mohammadi; Muzaffer Ahmed Bhat; Terence Li; Yan Sun; Seiya Kitamura; Edward Chu; Chaoyuan KuangShow moreShow less
Affiliations
Montefiore Einstein Comprehensive Cancer Center, Cancer Therapeutics Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461, USAShow moreShow less
49
days
Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota andl-serine metabolic pathway
Authors
Zhao Zhai; Feiya Yang; Ru Feng; Haojian Zhang; Jingyue Wang; Hengtong Zuo; Xinyu Yang; Mengliang Ye; Hui Xu; Jiachun Hu; Jinyue Lu; Yi Zhao; Jianye Song; Yong Zhang; Yan Wang; Nianzeng XingShow moreShow less
Affiliations
Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing 100050, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Urology, Peking University Cancer Hospital & Institute, Beijing 100089, ChinaShow moreShow less
120
days
Preclinical evaluation of a novel tetrazine probe within a pretargeted delivery system for theranostics in HER2-positive tumor-bearing mice models
Authors
Pengcheng Ma; Hui Tan; Qingyu Lin; Yuxia Liu; Hua Shen; Shuhua He; Hongxing Su; Zonghua Luo; Dai Shi; Dengfeng ChengShow moreShow less
Affiliations
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Shanghai Institute of Medical Imaging, Shanghai 200032, China; Department of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201210, China; Department of Applied Chemistry, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China; School of Biomedical Engineering & State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai 201210, ChinaShow moreShow less
109
days
APRIL-driven BCMA/TACI dual-targeted ligand–drug conjugates for selective and potent therapy of multiple myeloma
Authors
Linling Zhou; Yanping Sun; Jie Bi; Jiaqi Zhao; Yinli Xia; Jun He; Jisheng Wang; Liqiang PanShow moreShow less
Affiliations
School of Pharmacy and Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University, Hangzhou 310058, China; School of pharmacy, Hangzhou Medical College, Hangzhou 311399, China; The Third Hospital of Mianyang (Sichuan Mental Health center), Mianyang 612000, ChinaShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days